Facebook Pixel Code
Haematology/Oncology
Haematology/Oncology

Current Clinical Trials

*For eligibility criteria please click on the trial code. For additional information about current clinical trials and eligibility criteria, please contact our 

Clinical Trials Project Manager, Ceola Weir at nait.info@sickkids.ca

Trial Code

Summary

Trial
Status

Brain Tumours

Histio-
cytosis

Leukemia/
Lymphoma

Solid Tumours/
Neuro-
blastoma

 

BRF116013

Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study  to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumours.

 

 

Open

TOPAZ

 

A Phase I and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent or Refractory Solid Tumours Including CNS Tumours

 

Open

   

MEK116540

 

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate
the Safety, Pharma-
cokinetics, Pharma-
codynamics and Clinical
Activity of the MEK Inhibitor Trametinib in Children and
Adolescents Subjects with Cancer or Plexiform Neurofibromas
and Trametinib in Combination with Dabrafenib in Children and
Adolescents with Cancers Harboring V600 mutations

 

Open

 
N2004-05

Neuroblastoma Biology Studies New Approaches to Neuroblastoma Therapy (NANT) biology studies.

 

Open

     

 

      EZH-102

 A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

 

Temporarily closed to accrual

     

 

   N2011-01

Randomized Phase II Study of 131I-MIBG vs. 131I-MIBG with Vincristine and Irinotecan vs. 131I-MIBG with Vorinostat for Resistant/ Relapsed Neuroblastoma



Open

     

  ADVL1412

A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Open

   

Afatinib Pediatric Trial 1200-120

Phase I open label, dose escalation, monotherapy trial of afatinib to determine the MTD, safety, PK and efficacy of afatinib in children aged 6 months to <18 years with recurrent/refractory neuroectodermal tumours and rhabdomyosarcoma evaluating ErbB pathway deregulation

Open

   

KTE-C19

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

 

Open

   

 

 

 

 

 

 

CCTL019B2201X

Expanded treatment protocol for relapsed/refractory pediatric/young adult acute  lymphoblastic leukemia patients to be treated with CTL019

Open

   

 

  M13-833

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies

Open

   

  

    

BMS CA 209-908

Phase Ib/II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies

Open

              

OZM-077

Phase I/Ib trial of combined 5’azacitidine and carboplatin for recurrent/refractory pediatric brain and solid tumors and recurrent or refractory ependymoma

Open

   

N2015-02

Phase 1/2 study of PF-06463922, an oral small molecule inhibitor of ALK/ROS1, for patients with ALK-driven relapsed or refractory neuroblastoma

Open

                          

LOXO-TRK 15003

A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

Open

                     

MS100070-0306 

Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics,safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractory or relapsed solid tumors and lymphoma

Not yet open

                        

NANT 2015-01

 NEUROBLASTOMA PRECISION TRIAL

Not yet open 

       

Find a Paediatric Clinical Trial

For other clinical trials conducted in North America and around the world visit clinicaltrials.gov